Over the last few months our team has been busy attending a range of interesting conferences to discuss all things innovation and healthcare research.
We’ve attended conferences by some of the most interesting voices in the industry, including Intellus, JP Morgan Healthcare and Reuters, to learn about the latest trends in pharma, how they are set to shape the industry over the coming years, and how we can incorporate them into our work here at Adelphi.
Read on to find out more about the key topics that are driving change in pharma and what Adelphi can do to continue inspiring action in the industry.
Intellus Worldwide Summit
Top trends
In March Adelphi attended the Intellus Worldwide conference. Sessions were focused on topics such as recruitment, diversity and inclusion, quantitative analysis and more.
We found the sessions on diversity and inclusion particularly interesting, as they were approached from a patient recruitment and moderator training perspective.
We also had the opportunity to meet and talk with people at various recruitment consulting, and analytics firms, providing us with an opportunity to connect and see how we could beneficially work together.
Impact on pharma
Intellus was a great opportunity to support us in continuously building better industry connections, while the sessions themselves helped to inform on various topics to improve the quality of pharmaceutical medical research.
What we’re doing at Adelphi Research
We connected with several recruitment and full-service agencies, and the diversity and inclusion sessions helped us put a strong foot forward on a key client proposal and reinforced the need for our internal diversity and inclusion initiative.
J.P. Morgan Healthcare Conference
Top trends
Back in January we attended the J.P. Morgan Healthcare conference. Informal chats presented a more casual look into the 2023 outlook of major companies, including some high-level thoughts from our core clients, including:
- Lilly: Focused on diabetes and obesity, and the strength of their pipeline discussing four other potential launches this year.
- Novartis: Commented on being a ‘scaled pure play medicines company’ and focused on unique science (watch this video to learn more).
- GSK: Emphasis on vaccines, infectious disease and HIV moving forward.
- Merck: Focused on oncology growth drivers as well as non-oncology pipeline products.
Impact on pharma
J.P. Morgan Healthcare isn’t just an investor conference, but also a major place for initial meetings for venture capital funding for early biotechs, or larger mergers and acquisitions for established pharma companies. While not focused on healthcare research, it’s a great place to make contacts within pharma.
What we’re doing at Adelphi Research
The conference helped us to align our core clients’ business objectives and focuses for 2023, and inspired us to start Pharma Pulse, which has the potential to drive our business development initiatives forward through increasing our overall pharma and client knowledge.
Reuters Pharma
Top trends
In April we attended the Reuters Pharma conference. There were several key themes discussed over the course of the week, but the common thread running through the entire week was a focus on patient centricity and the customer experience.
Major themes discussed included health equity, digital health, AI tools, and omnichannel. ChatGPT was front and centre, with some very interesting sales rep tools being presented that significantly enhanced the sales experience and backend analytics measuring sales performance.
Impact on pharma
Opportunities like Reuters allow research companies to stay at the forefront of the pharmaceutical industry. While this conference is not tailored to medical research, it allows us to understand the priorities and trends within our client companies.
What we’re doing at Adelphi Research
We are continuing to innovate and make sure we stay on top of the AI tools available for our discipline. Awareness of what our clients are integrating into their businesses also allows us to better address their business challenges. Additionally, we continue to ensure we recruit more equitable samples and use moderators who are appropriate for particular sample populations.